News

Guardian Angel Senior Services Hires Lynne Alexandrowicz as Business Development Director

BILLERICA, Mass., Oct. 8, 2026 /PRNewswire/ — Guardian Angel Senior Services, a privately-owned senior home care company, is pleased announce the hire of Lynne Alexandrowicz as their new Business Development Director for Central and Western Massachusetts. The owners and leadership are… … […]

No Picture
Jobs

Co-Op, Bioanalytical and Molecular Assays – Norwood, MA

The Role Our Spring/Summer Co-op Program runs from January 18, 2027 through June 25, 2027. All applicants must be available for the full duration of the program. The Bioanalytical and Molecular Assay team is seeking a motivated co-op student to support laboratory-based bioanalytical LC-MS/MS activities for clinical programs…. Click here to view original post… […]

No Picture
News

eClinical Solutions Turns Clinical Data Intelligence Into Action at ENGAGE 2026

BOSTON–(BUSINESS WIRE)–eClinical Solutions LLC, a global provider of digital clinical software and services, will convene global technology and biopharma leaders October 12-14 for its eighth annual client and partner conference, ENGAGE 2026. The company will host over 250 attendees at W Philadelphia, including representatives from over 75 life science organizations… … […]

No Picture
News

CEO Innovation Policy Update 10.08.26

MassBio CEO & President Kendalle Burlin O’Connell originally posted this update to LinkedIn: With Congress out of Washington until after the November elections, the agencies continued to drive the life sciences policy agenda this week. Several developments are worth watching for Massachusetts biotechs, including the launch of a new FDA… … […]

News

Consano Bio to Highlight C-1101, Its Potential First-in-Class Disease-Modifying Therapeutic for Chronic Sciatica, at Upcoming October Conferences

BURLINGTON, Mass., Oct. 8, 2026 /PRNewswire/ — Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to address serious, painful orthopedic conditions, today announced that management will participate in two upcoming industry conferences to… … […]

No Picture
News

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM; ā€œCullinanā€), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer,Ā today announced that the first patient has been dosed in its pivotal Phase… … […]

No Picture
News

Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer

LEXINGTON, Mass.–(BUSINESS WIRE)—- $AGEN #Armenia–Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for BotvymoĀ® (botensilimab, BOT) and EvamplixĀ® (balstilimab, BAL), each approved for use in combination with the other for the treatment of… … […]